Capsida Biotherapeutics Debuts with $140 Million of Capital
- Versant, Westlake Village BioPartners launch next-generation gene therapy company with $50 million Series A -
- Collaboration with AbbVie provides $90 million in up front and equity investment capital to create tissue-targeted gene therapies for three CNS disease targets -
News provided by
Share this article
Share this article
THOUSAND OAKS, Calif., April 29, 2021 /PRNewswire/ Versant Ventures and Westlake Village BioPartners today announced the emergence from stealth mode of Capsida Biotherapeutics Inc., a biotechnology company using an adeno-associated virus (AAV) engineering and cargo development platform to develop tissue-targeted gene therapies for multiple types of diseases. In addition to a $50 million Series A commitment from the two firms, Capsida also announced a multi-year strategic collaboration and option agreement with AbbVie that provides $90 million in up front and equity investment capital in addit
MPM Capital Strengthens Team with the Addition of Neuroscience R&D Leader David S Bredt, MD, PhD as pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference
- BOTOX® (onabotulinumtoxinA) and BOTOX Cosmetic® clinical data across multiple therapeutic and aesthetic indications
- New analyses from CD-PROBE study evaluating sustained efficacy and tolerability of onabotulinumtoxinA in patients with cervical dystonia
- New analyses from the ASPIRE study on patient adherence to onabotulinumtoxinA for management of spasticity
- Data on onabotulinumtoxinA treatment in adult patients with overactive bladder and in pediatric patients with neurogenic detrusor overactivity
- Meta-analysis of immunogenicity rates across 10 therapeutic and aesthetic indications, and